Hims & Hers HealthHIMS
HIMS
About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Employees: 1,046
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
43% more call options, than puts
Call options by funds: $123M | Put options by funds: $85.6M
40% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]
35% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 48
4% more funds holding
Funds holding: 291 [Q2] → 302 (+11) [Q3]
9% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 91
2.54% less ownership
Funds ownership: 65.65% [Q2] → 63.11% (-2.54%) [Q3]
12% less capital invested
Capital invested by funds: $2.74B [Q2] → $2.42B (-$315M) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
56%
downside
Avg. target
$30
26%
downside
High target
$42
4%
upside
9 analyst ratings
5 positive
56%
2 neutral
22%
2 negative
22%
Citigroup Daniel Grosslight 43% 1-year accuracy 10 / 23 met price target | 38%downside $25 | Sell Downgraded | 10 Jan 2025 |
BTIG David Larsen 67% 1-year accuracy 12 / 18 met price target | 14%downside $35 | Buy Initiated | 7 Jan 2025 |
Piper Sandler Korinne Wolfmeyer 31% 1-year accuracy 15 / 48 met price target | 41%downside $24 | Neutral Maintained | 6 Jan 2025 |
Needham Ryan MacDonald 56% 1-year accuracy 38 / 68 met price target | 23%downside $31 | Buy Maintained | 6 Jan 2025 |
Morgan Stanley Craig Hettenbach 33% 1-year accuracy 2 / 6 met price target | 4%upside $42 | Overweight Initiated | 17 Dec 2024 |
Financial journalist opinion
Based on 22 articles about HIMS published over the past 30 days
Neutral
Zacks Investment Research
21 hours ago
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $42.20, representing a +0.84% change from its previous close.
Negative
Zacks Investment Research
1 day ago
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.
Neutral
Business Wire
2 days ago
Hims & Hers Launches Health Collective and Community Member Council
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced two new programs dedicated to serving its customers in even more personalized ways, encouraging customers to play an active role in the decisions and choices that shape their healthcare experience. The two groups, the Hims & Hers Health Collective, and the Hims & Hers Community Member Council, are born from the company's mission to help.
Neutral
Business Wire
3 days ago
Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2024 financial results after the market closes on Monday, February 24, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa.
Positive
Zacks Investment Research
3 days ago
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Neutral
Zacks Investment Research
1 week ago
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Negative
Zacks Investment Research
1 week ago
Hims & Hers Health, Inc. (HIMS) Increases Despite Market Slip: Here's What You Need to Know
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $31.86, signifying a +1.01% move from its prior day's close.
Negative
Seeking Alpha
1 week ago
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
I anticipate the FDA will soon declare the semaglutide shortage resolved, potentially slowing Hims' revenue growth rate due to compounding restrictions. I foresee explosive revenue growth post-FDA announcement due to 60-day timelines for pharmacies (503A) and 90-day timelines for outsourcing facilities (503B) to comply with the restrictions. I believe HIMS may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings, creating uncertainty for speculators betting against the stock.
Negative
The Motley Fool
1 week ago
Is Hims & Hers Health Stock a Buy?
Established in 2017, Hims & Hers Health (HIMS -1.17%) is a relatively young company addressing age-old healthcare challenges by offering prescription medications, over-the-counter products, and personal care solutions through a convenient direct-to-consumer model. Since going public via a special purpose acquisition company (SPAC) merger in 2021, the telehealth company and its stock have experienced dramatic transformations.
Neutral
Zacks Investment Research
2 weeks ago
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $29.72, signifying a -0.3% move from its prior day's close.
Charts implemented using Lightweight Charts™